All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 21, 2020
Details:
HitGen and Merck have expand their collaboration with a license to develop a novel class of drugs for an early target of high interest. HitGen will grant exclusive rights to Merck & Co., Inc Kenilworth, NJ USA to develop and commercialize the licensed compounds.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bispecific antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Aravive
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 30, 2020
Details:
Collaboration grants Aravive the right to use the proprietary WuXiBody™ platform to develop high-affinity bispecific antibodies for a target implicated in cancer and fibrosis.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
